{ "ok": true, "cik": "1357878", "ticker": null, "name": "REGENEREX PHARMA, INC.", "filings": [ { "form": "8-K", "filed": "2026-09-04", "items": [ "4.01 Changes in Registrant's Certifying Accountant", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1357878/000147237526000217/0001472375-26-000217-index.htm" }, { "form": "8-K", "filed": "2026-09-01", "items": [ "8.01 Other Events" ], "url": "https://www.sec.gov/Archives/edgar/data/1357878/000147237526000214/0001472375-26-000214-index.htm" }, { "form": "8-K", "filed": "2026-06-22", "items": [ "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1357878/000147237526000172/0001472375-26-000172-index.htm" }, { "form": "8-K", "filed": "2026-06-11", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1357878/000147237526000167/0001472375-26-000167-index.htm" }, { "form": "8-K", "filed": "2026-05-06", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers" ], "url": "https://www.sec.gov/Archives/edgar/data/1357878/000147237526000133/0001472375-26-000133-index.htm" }, { "form": "8-K", "filed": "2026-04-02", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers" ], "url": "https://www.sec.gov/Archives/edgar/data/1357878/000147237526000113/0001472375-26-000113-index.htm" } ], "events12m": 7, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001357878.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1357878" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up REGENEREX PHARMA, INC.. Last filing: 8-K (4.01 Changes in Registrant's Certifying Accountant), 2026-09-04. 7 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2026-09-04.", "auditor": { "changes": [ { "filed": "2026-09-04", "url": "https://www.sec.gov/Archives/edgar/data/1357878/000147237526000217/0001472375-26-000217-index.htm" } ], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2021-03-31", "revenue": 1775, "revenueGrowth1y": -0.31940184049079756, "revenueGrowthPerYear": null, "yearsOfData": 2, "operatingMargin": -24.456901408450705, "operatingMarginPrior": -29.52569018404908, "netMargin": -199.2969014084507, "operatingCashFlow": -62652, "capitalSpending": null, "freeCashFlow": null, "researchAndDevelopment": null, "researchShareOfRevenue": null, "cash": 6902, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2020-03-31", "revenue": 2608 }, { "fiscalYearEnd": "2021-03-31", "revenue": 1775 } ], "totalEquity": -835026, "totalAssets": 10470, "equityRatio": -79.75415472779369, "returnOnEquity": null, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": { "low": 886.5965059432515, "high": 1591.9837519171779, "baseline": 1208.0617331288342, "n": 749, "band": "b00" }, "ifPaceHeld": { "low": 886.5965059432515, "high": 1591.9837519171779 } }, "edgarette": "🔖 Exposure: revenue $2K (FY2021). Experience: revenue down 31.9% on the year; operating margin -2445.7%, up from -2952.6%. Soundness: equity -7975.4% of assets (liabilities exceed assets). Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $1K and $2K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A range, not a forecast. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -2445.7% against a -3.8% median; growth -31.9% against 13.7%.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Regenerex Pharma saw revenue fall 31.9% in FY2021 to $0 million, operating margin -2446% against a -3.8% median for pharmaceutical preparations, equity -7975% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
REGENEREX PHARMA, INC. against its own record and its peers
Operating marginPeer median -3.8%-2445.7%Revenue, on the yearPeer median 13.7%-31.9%Equity of assetsPeer median 40.3%-7975.4%Gold tick: the median of 118–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T14:14:06.394Z", "hash": "b02192786e209a83", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Regenerex Pharma saw revenue fall 31.9% in FY2021 to $0 million, operating margin -2446% against a -3.8% median for pharmaceutical preparations, equity -7975% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2021-03-31", "revenue": 1775, "totalDebt": null, "cash": 6902 }, "experience": { "revenueGrowth1y": -0.31940184049079756, "revenueGrowthPerYear": null, "operatingMargin": -24.456901408450705, "operatingMarginPrior": -29.52569018404908, "netMargin": -199.2969014084507, "freeCashFlow": null }, "soundness": { "equityRatio": -79.75415472779369, "returnOnEquity": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 2, "weight": "moderate", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": { "filed": "2026-09-04", "url": "https://www.sec.gov/Archives/edgar/data/1357878/000147237526000217/0001472375-26-000217-index.htm" } }, "range": { "low": 886.5965059432515, "high": 1591.9837519171779, "baseline": 1208.0617331288342, "coverage": 0.8, "method": "v3", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); range = 10th to 90th percentile of how SEC company-years of the same size band actually turned out", "calibratedOn": { "companyYears": 749, "sizeBand": "b00" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T14:14:06.394Z", "hash": "b02192786e209a83", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001357878.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1357878" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }